Cantor Fitzgerald initiated coverage on Pfizer with a new price target
$PFE
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/7/2026 | $25.00 | Neutral | UBS |
| 12/2/2025 | $26.00 | Neutral | Citigroup |
| 11/13/2025 | $30.00 | Sector Outperform | Scotiabank |
| 4/22/2025 | $24.00 | Neutral | Cantor Fitzgerald |
| 12/10/2024 | $29.00 | Neutral | BofA Securities |
| 11/15/2024 | $25.00 | Underperform | Wolfe Research |
| 10/25/2024 | $30.00 | Neutral | Citigroup |
| 10/17/2024 | $32.00 | Mkt Perform | Bernstein |
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
8-K - PFIZER INC (0000078003) (Filer)
8-K - PFIZER INC (0000078003) (Filer)
8-K - PFIZER INC (0000078003) (Filer)
Submission is to expand HYMPAVZI indication to the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patients (ages 6 to 11) without inhibitors If approved, HYMPAVZI would become the first non-factor prophylactic treatment available for children aged 6 to 11 years with hemophilia B Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the company's supplemental Biologics License Application (sBLA) for HYMPAVZI® (marstacimab) to expand the approved indication to include the treatment of hemophilia A or B patients 6 years and older with inhibitors, and pediatric patient
Program offers significant savings on over 30 brands spanning women's health, migraine, arthritis, rare disease and more Affirms Pfizer's commitment to reduce drug costs for millions of Americans through historic agreement with Trump administration Pfizer Inc. (NYSE:PFE) today announced the launch of its program on TrumpRx, making innovative medicines more affordable and accessible to millions of Americans. Starting today, the program provides Americans a wide range of more than 30 medicines at a significant discount off list prices. This effort is part of Pfizer's broader landmark Most Favored Nation (MFN) agreement with the U.S. government enabling patients to pay lower prices for
Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc
For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter
Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:
For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro
UBS resumed coverage of Pfizer with a rating of Neutral and set a new price target of $25.00
Citigroup resumed coverage of Pfizer with a rating of Neutral and set a new price target of $26.00
Scotiabank initiated coverage of Pfizer with a rating of Sector Outperform and set a new price target of $30.00
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
4 - PFIZER INC (0000078003) (Issuer)
Focused Execution Drives Strong Full-Year 2025 EPS Performance Enters 2026 with Clear Strategic Priorities and Growing Late-Stage Pipeline Advanced 11 Key Pivotal Study Starts in 2025 and ~20 Key Pivotal Study Starts Planned for 2026 Pfizer Inc. (NYSE:PFE) reported financial results for fourth-quarter and full-year 2025 and reaffirmed its full-year 2026 financial guidance(1) provided on December 16, 2025. EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and CEO of Pfizer: "With excellent execution in 2025, we delivered a solid financial performance and strengthened Pfizer's foundation for future growth. Looking ahead, 2026 will be an important year rich in key catalysts, inc
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 9:45 a.m. PST. To view and listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days. Abou
Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, February 3, 2026. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Fourth Quarter and Full Year 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen
Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham
Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T
DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid
SC 13G/A - PFIZER INC (0000078003) (Subject)
SC 13D - PFIZER INC (0000078003) (Filed by)
SC 13G/A - PFIZER INC (0000078003) (Subject)